Clovis Oncology, Inc.
CLVS
CLVS was delisted on the 20th of December, 2022.
165 hedge funds and large institutions have $953M invested in Clovis Oncology, Inc. in 2018 Q4 according to their latest regulatory filings, with 27 funds opening new positions, 61 increasing their positions, 54 reducing their positions, and 54 closing their positions.
75% more call options, than puts
Call options by funds: $57.6M | Put options by funds: $32.9M
13% more repeat investments, than reductions
Existing positions increased: 61 | Existing positions reduced: 54
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
14% less funds holding
Funds holding: 192 → 165 (-27)
42% less capital invested
Capital invested by funds: $1.63B → $953M (-$677M)
50% less first-time investments, than exits
New positions opened: 27 | Existing positions closed: 54
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$69.5M |
| 2 |
RG
Redmile Group
San Francisco,
California
|
+$46.6M |
| 3 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
+$21.5M |
| 4 |
SC
Samlyn Capital
New York
|
+$20.5M |
| 5 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$20.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$56.6M |
| 2 |
Franklin Resources
San Mateo,
California
|
-$51.7M |
| 3 |
CG
Carmignac Gestion
Paris,
France
|
-$44.5M |
| 4 |
PC
PointState Capital
New York
|
-$41M |
| 5 |
ACA
Avoro Capital Advisors
New York
|
-$33.7M |
CLVS Hedge Fund Activity: Q4 2018 in Review
165 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Clovis Oncology, Inc. (CLVS) for Q4 2018, worth a combined $953M — down 42% from $1.63B a quarter earlier.
Sellers outnumbered buyers: 54 funds closed out of CLVS and 27 opened new positions — a net loss of 27 holders — while 54 trimmed existing stakes and 61 added.
The largest buyer was Armistice Capital, adding an estimated $69.5M. The largest seller was PFM Health Sciences, exiting entirely with an estimated $56.6M sold.
- 165 institutional investors held Clovis Oncology, Inc. (CLVS) as of Q4 2018, down from 192 in Q3 2018.
- Funds reported $953M of Clovis Oncology, Inc. stock for Q4 2018, down 42% quarter-over-quarter.
- 27 funds opened new Clovis Oncology, Inc. positions in Q4 2018 and 54 closed out, a net change of -27 holders.
- The largest Clovis Oncology, Inc. buyer in Q4 2018 was Armistice Capital, an estimated $69.5M added.
- The largest Clovis Oncology, Inc. seller in Q4 2018 was PFM Health Sciences, an estimated $56.6M sold.
Based on aggregated 13F filings for Q4 2018.